2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Melanoma
273
Carcinoma, Non-Small-Cell Lung
244
Carcinoma, Renal Cell
143
Neoplasm Metastasis
99
Neoplasms
98
Squamous Cell Carcinoma of Head and Neck
88
Carcinoma, Hepatocellular
86
Colorectal Neoplasms
81
Lung Neoplasms
77
Stomach Neoplasms
59
Pancreatic Neoplasms
56
Carcinoma, Transitional Cell
50
Hodgkin Disease
47
Urinary Bladder Neoplasms
42
Head and Neck Neoplasms
42
Breast Neoplasms
40
Ovarian Neoplasms
37
Triple Negative Breast Neoplasms
34
Small Cell Lung Carcinoma
33
Brain Neoplasms
33
Sarcoma
32
Glioblastoma
32
Prostatic Neoplasms
31
Kidney Neoplasms
29
Recurrence
28
Multiple Myeloma
25
Esophageal Neoplasms
24
Uveal Melanoma
23
Skin Neoplasms
23
Uterine Cervical Neoplasms
22
Interventions
Carboplatin
7
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Observation
3
Neoadjuvant Therapy
3
Epirubicin
3
Endoscopy
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Monatide (IMS 3015)
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Nivolumab
×
Clear all
NCT03522246
2025-06-24
ATHENA
pharmaand GmbH
Phase 3
Active not recruiting
1,097 enrolled
26 charts